氢化可的松与脓毒性休克患者肾脏替代治疗需求的风险因素
该研究是对ADRENAL随机对照试验的事后队列分析,纳入3161例脓毒性休克患者,其中1589例随机接受氢化可的松、1572例接受安慰剂。主要结果显示,氢化可的松组需要肾脏替代治疗的发生率显著低于安慰剂组(21% vs 24%;OR 0.84,95%CI 0.70-0.99;P=0.04);校正相关因素后,氢化可的松仍与降低新发肾脏替代治疗需求显著相关(OR 0.79,95%CI 0.66-0.95;P=0.01)。在随机化后开始肾脏替代治疗的患者中,氢化可的松与无肾脏替代治疗生存天数无显著关联(平均差1.28天,95%CI -4.31至6.87;P=0.65)。
要点
- 脓毒性休克患者随机接受氢化可的松较安慰剂显著降低需要肾脏替代治疗的发生率(329例[21%] vs 372例[24%];OR 0.84,95%CI 0.70-0.99;P=0.04)。
- 校正与肾脏替代治疗需求相关的因素后,氢化可的松仍与降低新发肾脏替代治疗需求的几率显著相关(OR 0.79,95%CI 0.66-0.95;P=0.01)。
- 在随机化后开始肾脏替代治疗的患者中,氢化可的松未显著改善无肾脏替代治疗生存天数(平均差1.28天,95%CI -4.31至6.87;P=0.65)。
- 该分析纳入随机化前24小时内不需要肾脏替代治疗且无长期透析依赖的脓毒性休克患者。
适用人群与场景
- ADRENAL试验纳入的脓毒性休克患者,随机化前24小时内不需要肾脏替代治疗,且无既往长期透析依赖。
- 多中心ICU场景,涉及澳大利亚、英国、新西兰、沙特阿拉伯和丹麦的69个ICU,招募时间为2013年至2017年。
研究设计与关键结果
- 研究类型:对ADRENAL随机对照试验的事后队列分析;样本量3161例(氢化可的松组1589例,安慰剂组1572例);中位年龄65岁(IQR 53-74),男性1921例(61%)。
- 主要终点:氢化可的松组需要肾脏替代治疗的发生率显著低于安慰剂组(329例[21%] vs 372例[24%];OR 0.84,95%CI 0.70-0.99;P=0.04)。
- 校正与肾脏替代治疗需求相关的因素后,氢化可的松仍与降低新发肾脏替代治疗需求的几率显著相关(OR 0.79,95%CI 0.66-0.95;P=0.01)。
- 在随机化后开始肾脏替代治疗的患者中,氢化可的松与无肾脏替代治疗生存天数无显著关联(平均差1.28天,95%CI -4.31至6.87;P=0.65)。
证据类型、等级与局限
- 证据类型:对多中心安慰剂对照随机对照试验(ADRENAL)的事后队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在脓毒性休克患者中,使用氢化可的松可能降低新发肾脏替代治疗需求的风险,但该结果来自事后队列分析。
- 对于随机化后已开始肾脏替代治疗的患者,氢化可的松未显示改善无肾脏替代治疗生存天数。
指南或共识出处
- ADRENAL试验:Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock(脓毒性休克危重患者辅助糖皮质激素治疗),多中心安慰剂对照随机对照试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sepsis-associated acute kidney injury (SA-AKI) is a common and clinically important condition in patients who are critically ill. Dysregulated inflammation may contribute to it. Intravenous hydrocortisone may decrease the risk of SA-AKI progression.
OBJECTIVE: To describe the associations of hydrocortisone use with the incidence and outcomes of requirement for kidney replacement therapy (KRT), as well as source of sepsis, mean arterial pressure (MAP), and MAP indexed to required vasopressor (norepinephrine equivalent [NEE]).
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted as a post hoc analysis of the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) randomized clinical trial (RCT), a multicenter placebo-controlled RCT of hydrocortisone in patients with septic shock in 69 intensive care units in Australia, the United Kingdom, New Zealand, Saudi Arabia, and Denmark that recruited between 2013 and 2017. Participants were patients enrolled in the ADRENAL study with septic shock who did not require KRT in the 24 hours prior to randomization and who did not have a prior longstanding dialysis requirement. Data were analyzed between July and September 2024.
EXPOSURES: Receipt of hydrocortisone (vs placebo), MAP at enrollment, vasopressor dose (NEE) and MAP:NEE ratio, source of sepsis, causative organism, bacteremia, and the use of nephrotoxic antimicrobials, vasopressin, or specific inotropes.
MAIN OUTCOMES AND MEASURES: Outcomes of interest were KRT requirement and liberation from KRT, measured as days alive and free of KRT.
RESULTS: A cohort of 3161 patients (median [IQR] age, 65 [53-74] years, 1921 [61%] male) was identified, including 1589 patients randomized to receive hydrocortisone and 1572 patients who received the placebo. Allocation to treatment with hydrocortisone was associated with a significantly reduced incidence of KRT requirement compared with placebo (329 patients [21%] vs 372 patients [24%]; odds ratio [OR], 0.84 [95% CI, 0.70 to 0.99]; P = .04). When controlled for factors associated with KRT requirement, randomization to hydrocortisone remained significantly associated with a reduced odds of new KRT requirement (OR, 0.79 [95% CI, 0.66 to 0.95]; P = .01). Among patients who started KRT following randomization, hydrocortisone was not associated with reduced days alive and free of KRT (mean difference, 1.28 [95% CI, -4.31 to 6.87] days; P = .65).
CONCLUSIONS AND RELEVANCE: In this post hoc cohort study of patients with septic shock enrolled in a large RCT, intravenous hydrocortisone was associated with a reduced risk of new KRT requirement following randomization.
参考来源
- Donaldson LH, Devaux A, White KC, et al. Hydrocortisone and Risk Factors for Kidney Replacement Therapy in Septic Shock. JAMA Netw Open. 2025. PMID: 40423970. doi:10.1001/jamanetworkopen.2025.12279
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。